On Monday, Citi maintained its Neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA), with a price target set at $29.00. The firm's analysis followed new data presented by Intellia at the European Academy of Allergy and Clinical Immunology (EAACI) regarding its therapy, NTLA-2002, which demonstrated a significant reduction in monthly hereditary angioedema (HAE) attacks.
Intellia revealed that its NTLA-2002 therapy led to a 98% decrease in the frequency of monthly HAE attacks, along with a consistent safety profile. Despite the limited number of patients, the therapy showed a competitive edge in key metrics including reductions in monthly attacks, number of treated attacks, and moderate-to-severe attacks.
The firm noted that while NTLA-2002 could offer substantial benefits to patients with severe HAE, it is expected to see niche utilization. This is attributed to the availability of other effective therapies and potential hesitations regarding the irreversible nature of gene editing.
Highlighting individual outcomes, Citi pointed out that two patients with historically high baseline attack frequencies experienced no attacks for over 20 months following treatment with NTLA-2002, indicating the therapy's potential strength.
Further insights are anticipated from Intellia's webcast, which was scheduled for Monday at 8 a.m. ET. The discussion is expected to cover topics such as the variability and durability of kallikrein knockdown, the implications of low-grade liver enzyme elevations, and what to expect from the NTLA-2002 Phase 2 study's topline update, projected for mid-2024.
InvestingPro Insights
As Intellia Therapeutics (NASDAQ:NTLA) continues to make strides with its NTLA-2002 therapy, it's important for investors to consider the financial health and market performance of the company. According to real-time data from InvestingPro, Intellia holds a market capitalization of $2.06 billion. Despite a challenging revenue growth of -1.63% over the last twelve months as of Q1 2024, the company has shown a remarkable quarterly revenue growth of 129.53% in Q1 2024. This suggests a potential for significant financial improvement in the short term, aligning with the advancements in their therapy programs.
An InvestingPro Tip highlights that Intellia holds more cash than debt on its balance sheet, which is a strong indicator of financial stability and may provide the company with the flexibility to continue its research and development efforts. Additionally, analysts have revised their earnings upwards for the upcoming period, reflecting an optimistic outlook on the company's future performance.
Investors interested in a deeper analysis can find additional InvestingPro Tips for Intellia, which provide further insights into the company's financial metrics and projections. With the coupon code PRONEWS24, readers can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription to access these valuable tips.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.